BIOMAT Database Logo BIOMAT Database Logo

Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients. 2022

Kyoko Ikumi, and Kan Torii, and Yoko Sagawa, and Yoshifumi Kanayama, and Aya Nakada, and Haruna Nishihara, and Akimichi Morita
Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

UI MeSH Term Description Entries
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D013792 Thalidomide A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. Sedoval,Thalomid
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D058988 Phosphodiesterase 4 Inhibitors Compounds that specifically inhibit PHOSPHODIESTERASE 4. PDE-4 Inhibitor,PDE4 Inhibitor,Phosphodiesterase 4 Inhibitor,Phosphodiesterase Type 4 Inhibitor,PDE-4 Inhibitors,PDE4 Inhibitors,Phosphodiesterase Type 4 Inhibitors,4 Inhibitor, Phosphodiesterase,Inhibitor, PDE-4,Inhibitor, PDE4,Inhibitor, Phosphodiesterase 4,Inhibitors, PDE-4,Inhibitors, PDE4,Inhibitors, Phosphodiesterase 4,PDE 4 Inhibitor,PDE 4 Inhibitors

Related Publications

Kyoko Ikumi, and Kan Torii, and Yoko Sagawa, and Yoshifumi Kanayama, and Aya Nakada, and Haruna Nishihara, and Akimichi Morita
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
February 2010, British journal of pharmacology,
Kyoko Ikumi, and Kan Torii, and Yoko Sagawa, and Yoshifumi Kanayama, and Aya Nakada, and Haruna Nishihara, and Akimichi Morita
Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.
December 2014, Rheumatology and therapy,
Kyoko Ikumi, and Kan Torii, and Yoko Sagawa, and Yoshifumi Kanayama, and Aya Nakada, and Haruna Nishihara, and Akimichi Morita
Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
March 2017, Journal of the European Academy of Dermatology and Venereology : JEADV,
Kyoko Ikumi, and Kan Torii, and Yoko Sagawa, and Yoshifumi Kanayama, and Aya Nakada, and Haruna Nishihara, and Akimichi Morita
Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
October 2015, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Kyoko Ikumi, and Kan Torii, and Yoko Sagawa, and Yoshifumi Kanayama, and Aya Nakada, and Haruna Nishihara, and Akimichi Morita
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
September 2013, Annals of the rheumatic diseases,
Kyoko Ikumi, and Kan Torii, and Yoko Sagawa, and Yoshifumi Kanayama, and Aya Nakada, and Haruna Nishihara, and Akimichi Morita
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
July 2015, Journal of the American Academy of Dermatology,
Kyoko Ikumi, and Kan Torii, and Yoko Sagawa, and Yoshifumi Kanayama, and Aya Nakada, and Haruna Nishihara, and Akimichi Morita
Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast.
March 2016, JAMA dermatology,
Kyoko Ikumi, and Kan Torii, and Yoko Sagawa, and Yoshifumi Kanayama, and Aya Nakada, and Haruna Nishihara, and Akimichi Morita
Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata.
August 2019, European journal of dermatology : EJD,
Kyoko Ikumi, and Kan Torii, and Yoko Sagawa, and Yoshifumi Kanayama, and Aya Nakada, and Haruna Nishihara, and Akimichi Morita
A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast.
November 2018, Acta dermato-venereologica,
Kyoko Ikumi, and Kan Torii, and Yoko Sagawa, and Yoshifumi Kanayama, and Aya Nakada, and Haruna Nishihara, and Akimichi Morita
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.
September 2015, Arthritis research & therapy,
Copied contents to your clipboard!